Opinions Geoff Houlton
Microbix BiosystemsMBX.TOWEAK BUYMar 26, 2008
Been around for a long time. Has a broad range of technologies. Have recently signed licensed for Virusmax, which can double the yield of virus production for vaccinations. Bull semen-sexing technology. Have some very interesting technologies. Watching it very closely. Like the company.
$0.76
Stock price when the opinion was issued
$0.29
As of Aug 04, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
BUY
Very positive on the stock price, the company, and the partnerships they're announcing. Technicals indicate the stock may head toward 90 cents, but he says higher. Just won a contract from the Ontario government. Covid testing isn't going away. Sales should triple in the next 12 months.
Robert McWhirterOwned
biotechnologypharmaceutical
TOP PICK
They're involved in Covid testing. Sales should more than double by Sept. 2021 year end to $25 million with a further 32% growth in sales of 2022 to $34 million. He expects Covid testing will continue to be common for employees and travellers. This stock could double from current levels. Other analysts target even higher, but this is a speculative stock. (Analysts’ price target is $0.80)
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 17/19, Down 7%) He still holds this one. He participated in a financing about four months ago. They produce tests for HPV, but unfortunately COVID-19 has taken center stage. He likes their quality assessment tests and the outlook remains positive.
Robert McWhirterOwned
biotechnologypharmaceutical
STRONG BUY
He still likes it and holds it. It makes cell culture measurements. They moved over to a more economical method for making their products and this will benefit their profitability. They have a division up for sale and they might get lucky and get a sale before year-end.
Robert McWhirterOwned
biotechnologypharmaceutical
TOP PICK
A very thinly traded stock. They are involved in biomedical testing. They reported earnings up 40%. He sees great opportunity to increase capacity. He expects a 13 times PE going forward -- very reasonable. ROE 15%. His third largest holding. Yield 0% (Analysts’ price target is $0.71)
Robert McWhirterOwned
biotechnologypharmaceutical
WEAK BUY
Doing a number of things in the animal area. Interested in it. There should be some dramatic catalysts this year.
Hugh Cleland, CFAOwned
biotechnologypharmaceutical
